Research programme: kinase inhibitors - Onconic Therapeutics
Latest Information Update: 30 Apr 2021
At a glance
- Originator Onconic Therapeutics
- Class Antineoplastics
- Mechanism of Action Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cancer
Most Recent Events
- 21 Apr 2021 Kinase inhibitors - Onconic Therapeutics is available for licensing as of 21 Apr 2021. http://onconic.co.kr/about/company.php
- 21 Apr 2021 Early research in Cancer in South Korea (unspecified route) before April 2021 (Onconic Therapeutics pipeline, April 2021)